IRIS
VITA, GIANLUCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.142
NA - Nord America 4.721
AS - Asia 3.543
SA - Sud America 1.285
AF - Africa 107
Continente sconosciuto - Info sul continente non disponibili 14
OC - Oceania 9
Totale 14.821
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.615
RU - Federazione Russa 1.727
SG - Singapore 1.637
BR - Brasile 1.130
CN - Cina 955
IE - Irlanda 902
SE - Svezia 608
IT - Italia 515
DE - Germania 385
HK - Hong Kong 374
PL - Polonia 330
VN - Vietnam 230
FI - Finlandia 179
GB - Regno Unito 149
FR - Francia 130
IN - India 92
UA - Ucraina 80
AR - Argentina 64
MX - Messico 49
CA - Canada 41
BD - Bangladesh 33
BE - Belgio 32
TR - Turchia 32
ZA - Sudafrica 29
CI - Costa d'Avorio 28
ID - Indonesia 28
AT - Austria 27
JP - Giappone 26
IQ - Iraq 25
EC - Ecuador 24
VE - Venezuela 19
MA - Marocco 15
NL - Olanda 15
CZ - Repubblica Ceca 13
ES - Italia 13
LT - Lituania 13
PK - Pakistan 12
UZ - Uzbekistan 12
CO - Colombia 11
KE - Kenya 11
CL - Cile 10
AE - Emirati Arabi Uniti 9
EU - Europa 9
PY - Paraguay 9
TN - Tunisia 9
AZ - Azerbaigian 8
JO - Giordania 8
KZ - Kazakistan 8
PE - Perù 8
IL - Israele 7
NP - Nepal 7
EG - Egitto 6
AU - Australia 5
CR - Costa Rica 5
UY - Uruguay 5
NZ - Nuova Zelanda 4
SK - Slovacchia (Repubblica Slovacca) 4
CY - Cipro 3
GY - Guiana 3
HU - Ungheria 3
IR - Iran 3
KG - Kirghizistan 3
KR - Corea 3
KW - Kuwait 3
LB - Libano 3
MY - Malesia 3
PA - Panama 3
PH - Filippine 3
SA - Arabia Saudita 3
XK - ???statistics.table.value.countryCode.XK??? 3
BO - Bolivia 2
BY - Bielorussia 2
DO - Repubblica Dominicana 2
GA - Gabon 2
LK - Sri Lanka 2
OM - Oman 2
PS - Palestinian Territory 2
RO - Romania 2
RS - Serbia 2
SN - Senegal 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BH - Bahrain 1
BN - Brunei Darussalam 1
CG - Congo 1
CH - Svizzera 1
DZ - Algeria 1
EE - Estonia 1
GE - Georgia 1
GI - Gibilterra 1
GR - Grecia 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
JM - Giamaica 1
Totale 14.810
Salva come PNG Salva come JPEG
Città #
Moscow 913
Dublin 902
Ashburn 643
Chandler 624
Dallas 588
Singapore 560
Beijing 418
Nyköping 380
Hong Kong 374
Warsaw 318
Jacksonville 235
Princeton 177
Medford 141
Ann Arbor 137
Messina 135
The Dalles 127
Los Angeles 122
Cambridge 115
Munich 92
Des Moines 89
Ho Chi Minh City 88
New York 84
São Paulo 76
Boardman 64
Buffalo 62
Dearborn 62
Bremen 59
Lancaster 59
Shenyang 57
Pune 53
San Mateo 49
Tianjin 49
Turku 47
Wilmington 43
Jinan 42
Redondo Beach 41
Rio de Janeiro 39
Hanoi 37
Houston 36
Belo Horizonte 32
Brussels 30
Nanjing 30
Rome 30
Abidjan 28
Frankfurt am Main 27
Tokyo 24
Hebei 23
Ningbo 23
Zhengzhou 23
Brooklyn 22
Hangzhou 22
Helsinki 22
Porto Alegre 22
Brasília 21
Curitiba 21
Dong Ket 20
Atlanta 17
Council Bluffs 17
Nürnberg 17
Stockholm 15
Toronto 15
Woodbridge 15
Salvador 14
Guangzhou 13
Johannesburg 13
Montreal 13
Palo Del Colle 13
Santa Clara 13
Taizhou 13
Baghdad 12
Catania 12
Changsha 12
Chicago 12
Jakarta 12
London 12
Mexico City 12
Nanchang 12
Nuremberg 12
Orem 12
Seattle 12
Amsterdam 11
Haikou 11
Hyderabad 11
Milan 11
Norwalk 11
Poplar 11
Tashkent 11
Vienna 11
Campinas 10
Denver 10
Guarulhos 10
Juiz de Fora 10
Osasco 10
San Jose 10
Boston 9
Chennai 9
Dhaka 9
Düsseldorf 9
Guadalupe 9
Manchester 9
Totale 9.079
Salva come PNG Salva come JPEG
Nome #
Psychosocial impact of presymptomatic genetic testing for amyloidotic polyneuropathy 263
6MWT performance correlates with peripheral neuropathy but not with cardiac involvement in patients with hereditary transthyretin amyloidosis (hATTR) 256
Severe rhabdomyolysis in a patient with “Heat Stroke” 250
Clinical and pathological features of focal myositis 234
Psychosocial impact of presymptomatic genetic testing for amyloidotic polyneuropathy 230
A Phase 1/2 Study of Flavocoxid, an Oral NF-κB Inhibitor, in Duchenne Muscular Dystrophy 195
24 month longitudinal data in ambulant boys with Duchenne muscular dystrophy. 172
Circulating miRNAs expression as potential biomarkers of mild traumatic brain injury 168
Circulating microRNAs Profile in Patients With Transthyretin Variant Amyloidosis 167
Anabolic treatment with RHPTH of duchenne muscular dystrophy related osteoporosis: a case report 159
Health-related quality of life and functional changes in DMD: A 12-month longitudinal cohort study 156
Hippo signaling pathway is altered in Duchenne muscular dystrophy 153
microRNA-10 and -221 modulate differential expression of Hippo signaling pathway in human astroglial tumors 148
Parenteral nutrition improves nutritional status, autonomic symptoms and quality of life in transthyretin amyloid polyneuropathy 145
Autonomic nervous system involvement in spinal muscular atrophy. 145
Modulation of neuronal nitric oxide synthase and apoptosis by the isoflavone genistein in Mdx mice 143
Intrathecal administration of Nusinersen in type 1 SMA: successful psychological program in a single Italian center 139
Which are the factors influencing NIV adaptation and tolerance in ALS patients? 139
ANT1 expression and RAGE-NF-kB pathway in sporadic inclusion body myositis. 138
ANT1 is reduced in sporadic inclusion body myositis. 136
Effect of exercise on telomere length and telomere proteins expression in mdx mice 133
Nusinersen versus sham control in later-onset spinal muscular atrophy 133
Pilot study of serial casting in muscular dystrophy patients. 127
Pilot study of serial casting of ankles in muscular dystrophy patients. 126
Benefits of glucocorticoids in non-ambulant boys/men with Duchenne muscular dystrophy: A multicentric longitudinal study using the Performance of Upper Limb test 125
Pilot study of flavocoxid in ambulant DMD patients. 125
The 24-month PUL changes and steroids correlation. 125
Predictors of adaptation to non-invasive ventilation in amyotrophic lateral sclerosis 124
Neuropsychological patter in centronuclear myopathy due to DNM2 gene mutations. 123
6 Minute Walk Test in Duchenne MD Patients with Different Mutations: 12 Month Changes 122
Sport activity in Charcot-Marie-Tooth disease: A case study of a Paralympic swimmer 118
BONE INVOLVEMENT IN DUCHENNE MUSCULAR DYSTROPHY 118
Telomere shortening and telomere-associated proteins in Duchenne muscular dystrophy. 117
Genetic Modifiers of Duchenne Muscular Dystrophy and Dilated Cardiomyopathy 117
First report of a family with a DMD out of frame exon 2 deletion associated with asymptomatic phenotypes. 117
Outcome measures in Duchenne muscular dystrophy: validation of the Pediatric Quality of Life InventoryTM Neuromuscular Module in the Italian population and correlation with other functional assessments. 117
Bone health in Duchenne muscular dystrophy: clinical and biochemical correlates 117
Modulation of neural nitric oxide synthase by the isoflavone genistein promotes muscle regeneration in mdx mice 116
Activation of NF-kappaB pathway in Duchenne muscular dystrophy: relation to age 116
Psycological status and emotional burden in amyotrophic lateral sclerosis caregivers: the role of metacognitive processes. 115
Integrated care of muscular dystrophies in Italy. Part 1. Pharmacological treatment and rehabilitative interventions 115
Telomere shortening is associated to TRF1 and PARP1 overexpression in Duchenne muscular dystrophy 114
Novel outcome measures for Charcot-Marie-Tooth disease: Validation and reliability of the 6-min walk test and StepWatch™ Activity Monitor and identification of the walking features related to higher quality of life 113
Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 1: peripheral neuropathies 113
Psychosocial impact of sport activity in neuromuscular disorders 113
Pilot study of flavocoxid in ambulant DMD patients. 112
Severe rhabdomyolysis in a patient with “Heat Stroke” 112
Impaired myocardial deformation revealing subclinical left ventricular dysfunction in children with Duchenne dystrophy: a speckle tracking echocardiography study 112
Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes 111
Pilot study of flavocoxid in ambulant DMD patients. 111
Histological effects of givinostat in boys with Duchenne muscular dystrophy 110
Integrated care of muscular dystrophies in Italy. Part 2. Psychological treatments, social and welfare support, and financial costs 110
Cardiac function in types II and III spinal muscular atrophy: should we change standards of care? 110
The soy isoflavone genistein blunts nuclear factor kappa-B, MAPKs and TNF-α activation and ameliorates muscle function and morphology in mdx mice. 110
Parenteral nutrition improves nutritional status, autonomic symptoms and qol in patients with TTR-FAP 109
Impaired myocardial strain in early stage of Duchenne muscular dystrophy: its relation with age and motor performance 109
Teriparatide (rhPTH 1-34) in Duchenne Muscular Dystrophy related osteoporosis: a case report 108
Burden, professional support, and social network in families of children and young adults with muscular dystrophies 108
Predictors of adaptation to non-invasive ventilation in neuromuscular disorders. 107
ANT1 expression and RAGE-NF-kB pathway in sporadic inclusion body myositis 107
Espressione di ANT1 e attivazione della via RAGE-NF-kB nella miosite a corpi inclusi. 106
Muscle Fat-Fraction and Mapping in Duchenne Muscular Dystrophy: Evaluation of Disease Distribution and Correlation with Clinical Assessments: A preliminary experience. 106
Impaired rotational mechanics and strain revealing subclinical left ventricular dysfunction in children with neuromuscolar disorders: a speckle tracking study 106
First report of a family with a DMD out of frame exon 2 deletion associated with asymptomatic phenotypes. 106
Effects of teriparatide on bone mineral density and quality of life in Duchenne muscular dystrophy related osteoporosis: a case report 106
Burden, social network and professional support in the families of patients with muscular dystrophies: results from the GUP10002 study. 104
Impaired rotational mechanics and strain revealing subclinical left ventricular dysfunction in children with Duchenne muscular dystrophy: a skeckle tracking study. 102
Emergenze respiratorie nelle malattie neurologiche 102
Amyloid myopathy presenting with rhabdomyolysis. 101
Teriparatide (rhPTH 1-34) in Duchenne Muscular Dystrophy related osteoporosis: a case report. 101
Clinical variability in spinal muscular atrophy type III 101
Selective short-term verbal memory involvement in two siblings carrying centronuclear myopathy due to DNM2 gene mutations 100
Bone quality in Duchenne muscular dystrophy 100
study of flavocoxid in ambulant DMD patients. 99
6 min walking test 12 month changes in DMD: Correlation with genotype. 99
Timed rise from floor as a predictor of disease progression in Duchenne muscular dystrophy: An observational study 99
Psychological and practical difficulties among parents and healthy siblings of children with Duchenne vs. Becker muscular dystrophy: an Italian comparative study 95
Teriparatide (rhPTH) treatment in Duchenne Muscular Dystrophy, a case report. 95
Dual-echo dual flip angle gradient-echo MRI technique for quantification of muscle fat fraction in Duchenne muscular dystrophy: a new valuable outcome measure. 94
Telomere shortening and telomere associated proteins in exercised wild type and mdx mice. 94
MYH7-related myopathies: Clinical, histopathological and imaging findings in a cohort of Italian patients 92
Miopatia prossimale in paziente con sindrome di Williams 90
Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 2: diseases of motor neuron and skeletal muscle 90
Implication of SIRT1 and its downstream pathways in dystrophic process. 90
The 6 minute walk test and performance of upper limb in ambulant duchenne muscular dystrophy boys 89
Pilot study of flavocoxid in ambulant DMD patients. 89
Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy 86
Dolori muscolari, deficit di forza e/o disturbi sensitivi 86
Psychosocial impact of presymptomatic genetic testing for transthyretin amyloidotic polyneuropathy 85
Flavocoxid counteracts muscle necrosis and improves functional properties in mdx mice: a comparison study with methylprednisolone 85
Respiratory Emergencies in Neurological Diseases 85
The first report of a patient carrying an out-of-frame exon2 deletion in the dystrophin gene and showing a very unusual phenotype. 84
Practical approach to respiratory emergencies in neurological diseases 84
L'inibizione dei pathway del fattore nucleare-kappaB, delle MAP chinasi e di COX/5-LOX mediante trattamento con flavocoxid migliora la funzione e la morfologia muscolare nel topo mdx: uno studio comparativo con il metilprednisolone 83
Role of calcineurin/NFAT on muscle regeneration in dystrophic process. 81
Reliability of the Performance of Upper Limb assessment in Duchenne muscular dystrophy 81
FSHD and Williams syndrome: the occurrence of two genetic disorders due to heterozygous DNA fragment deletions in the same patient. 80
The Genetic Landscape of Dystrophin Mutations in Italy: A Nationwide Study 78
Safety and effectiveness of ataluren: comparison of results from the STRIDE Registry and CINRG DMD Natural History Study 77
Diagnosis of Duchenne Muscular Dystrophy in Italy in the last decade: Critical issues and areas for improvements 75
Totale 11.887
Salva come PNG Salva come JPEG
Categoria #
all - tutte 55.309
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 55.309
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021343 0 0 0 0 0 52 74 41 22 80 36 38
2021/2022957 10 97 4 64 48 6 95 38 33 94 88 380
2022/20232.417 196 230 125 160 204 203 18 115 1.092 6 57 11
2023/2024734 31 116 35 83 55 176 37 41 5 32 25 98
2024/20253.404 61 45 39 192 91 84 77 645 726 191 538 715
2025/20265.000 475 621 704 681 730 1.789 0 0 0 0 0 0
Totale 15.188